Glycomic approaches for the discovery of targets in gastrointestinal cancer

Frontiers in Oncology

Volumn 6, Issue MAR, 2016, Pages

  Mereiter, Stefan ^a,b   Balmaña, Meritxell ^c   Gomes, Joana ^a,b   Magalhães, Ana ^a,b   Reis, Celso A ^a,b,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF GIRONA   (Spain)

^d University of Porto   (Portugal)

Author keywords

Colorectal cancer; Gastric cancer; Glycan biomarkers; Glycomics; Imaging mass spectrometry; Microarray; Pancreatic cancer; Proximity ligation assay

Indexed keywords

HERMES ANTIGEN;

CANCER DIAGNOSIS; CANCER GROWTH; CELL ADHESION; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; ELECTROSPRAY; FUCOSYLATION; GLYCOSYLATION; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTASIS; MICROARRAY ANALYSIS; PANCREAS CANCER; PROTEOMICS; REVIEW; SIALYLATION; SURVIVAL RATE; TUMOR INVASION;

EID: 84964430153     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00055     Document Type: Review

References (220)

1. Reis CA, Osorio H, Silva L, Gomes C, David L. Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol (2010) 63(4):322-9. doi:10.1136/jcp.2009.071035
2. Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer (2015) 15(9):540-55. doi:10.1038/nrc3982
3. Stowell SR, Ju T, Cummings RD. Protein glycosylation in cancer. Annu Rev Pathol (2015) 10:473-510. doi:10.1146/annurev-pathol-012414-040438
4. Rabinovich GA, Croci DO. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity (2012) 36(3):322-35. doi:10.1016/j.immuni.2012.03.004
5. Boligan KF, Mesa C, Fernandez LE, von Gunten S. Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense. Cell Mol Life Sci (2015) 72(7):1231-48. doi:10.1007/s00018-014-1799-5
6. Sangadala S, Bhat UR, Mendicino J. Quantitation and structures of oligosaccharide chains in human trachea mucin glycoproteins. Mol Cell Biochem (1992) 118(1):75-90. doi:10.1007/BF00249697
7. Kudelka MR, Ju T, Heimburg-Molinaro J, Cummings RD. Simple sugars to complex disease-mucin-type O-glycans in cancer. Adv Cancer Res (2015) 126:53-135. doi:10.1016/bs.acr.2014.11.002
8. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep (2006) 7(6):599-604. doi:10.1038/sj.embor.7400705
9. Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA, Tabak LA. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology (2012) 22(6):736-56. doi:10.1093/glycob/cwr182
10. Clausen H, Bennett EP. A family of UDP-GalNAc: polypeptide N-acetylgalactosaminyl-transferases control the initiation of mucin-type O-linked glycosylation. Glycobiology (1996) 6(6):635-46. doi:10.1093/glycob/6.6.635
11. Gomes J, Marcos NT, Berois N, Osinaga E, Magalhaes A, Pinto-de-Sousa J, et al. Expression of UDP-N-acetyl-d-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma. J Histochem Cytochem (2009) 57(1):79-86. doi:10.1369/jhc.2008.952283
12. Shibao K, Izumi H, Nakayama Y, Ohta R, Nagata N, Nomoto M, et al. Expression of UDP-N-acetyl-alpha-d-galactosamine-polypeptide galNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma. Cancer (2002) 94(7):1939-46. doi:10.1002/cncr.10423
13. Taniuchi K, Cerny RL, Tanouchi A, Kohno K, Kotani N, Honke K, et al. Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth. Oncogene (2011) 30(49):4843-54. doi:10.1038/onc.2011.194
14. Gill DJ, Clausen H, Bard F. Location, location, location: new insights into O-GalNAc protein glycosylation. Trends Cell Biol (2011) 21(3):149-58. doi:10.1016/j.tcb.2010.11.004
15. Hua D, Shen L, Xu L, Jiang Z, Zhou Y, Yue A, et al. Polypeptide N-acetylgalactosaminyltransferase 2 regulates cellular metastasis-associated behavior in gastric cancer. Int J Mol Med (2012) 30(6):1267-74. doi:10.3892/ijmm.2012.1130
16. Dalziel M, Whitehouse C, McFarlane I, Brockhausen I, Gschmeissner S, Schwientek T, et al. The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1. J Biol Chem (2001) 276(14):11007-15. doi:10.1074/jbc. M006523200
17. Marcos NT, Pinho S, Grandela C, Cruz A, Samyn-Petit B, Harduin-Lepers A, et al. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res (2004) 64(19):7050-7. doi:10.1158/0008-5472.CAN-04-1921
18. Marcos NT, Bennett EP, Gomes J, Magalhaes A, Gomes C, David L, et al. ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. Front Biosci (Elite Ed) (2011) 3:1443-55
19. David L, Nesland JM, Clausen H, Carneiro F, Sobrinho-Simoes M. Simple mucin-type carbohydrate antigens (Tn, sialosyl-Tn and T) in gastric mucosa, carcinomas and metastases. APMIS Suppl (1992) 27:162-72
20. Pinho S, Marcos NT, Ferreira B, Carvalho AS, Oliveira MJ, Santos-Silva F, et al. Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett (2007) 249(2):157-70. doi:10.1016/j.canlet.2006.08.010
21. Itzkowitz S, Kjeldsen T, Friera A, Hakomori S, Yang US, Kim YS. Expression of Tn, sialosyl Tn, and T antigens in human pancreas. Gastroenterology (1991) 100(6):1691-700
22. Itzkowitz SH, Yuan M, Montgomery CK, Kjeldsen T, Takahashi HK, Bigbee WL, et al. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res (1989) 49(1):197-204
23. Radhakrishnan P, Dabelsteen S, Madsen FB, Francavilla C, Kopp KL, Steentoft C, et al. Immature truncated O-glycophenotype of cancer directly induces oncogenic features. Proc Natl Acad Sci U S A (2014) 111(39):E4066-75. doi:10.1073/pnas.1406619111
24. Hofmann BT, Schluter L, Lange P, Mercanoglu B, Ewald F, Folster A, et al. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer. Mol Cancer (2015) 14:109. doi:10.1186/s12943-015-0386-1
25. Ju T, Cummings RD. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc Natl Acad Sci U S A (2002) 99(26):16613-8. doi:10.1073/pnas.262438199
26. Chik JH, Zhou J, Moh ES, Christopherson R, Clarke SJ, Molloy MP, et al. Comprehensive glycomics comparison between colon cancer cell cultures and tumours: implications for biomarker studies. J Proteomics (2014) 108:146-62. doi:10.1016/j.jprot.2014.05.002
27. Hung JS, Huang J, Lin YC, Huang MJ, Lee PH, Lai HS, et al. C1GALT1 overexpression promotes the invasive behavior of colon cancer cells through modifying O-glycosylation of FGFR2. Oncotarget (2014) 5(8):2096-106. doi:10.18632/oncotarget.1815
28. Shimodaira K, Nakayama J, Nakamura N, Hasebe O, Katsuyama T, Fukuda M. Carcinoma-associated expression of core 2 beta-1,6-N-acetylglucosaminyltransferase gene in human colorectal cancer: role of O-glycans in tumor progression. Cancer Res (1997) 57(23):5201-6
29. Remmers N, Anderson JM, Linde EM, DiMaio DJ, Lazenby AJ, Wandall HH, et al. Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer. Clin Cancer Res (2013) 19(8):1981-93. doi:10.1158/1078-0432.CCR-12-2662
30. Iwai T, Kudo T, Kawamoto R, Kubota T, Togayachi A, Hiruma T, et al. Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc Natl Acad Sci U S A (2005) 102(12):4572-7. doi:10.1073/pnas.0407983102
31. Rossez Y, Maes E, Lefebvre Darroman T, Gosset P, Ecobichon C, Joncquel Chevalier Curt M, et al. Almost all human gastric mucin O-glycans harbor blood group A, B or H antigens and are potential binding sites for Helicobacter pylori. Glycobiology (2012) 22(9):1193-206. doi:10.1093/glycob/cws072
32. Kenny DT, Skoog EC, Linden SK, Struwe WB, Rudd PM, Karlsson NG. Presence of terminal N-acetylgalactosaminebeta1-4N-acetylglucosamine residues on O-linked oligosaccharides from gastric MUC5AC: involvement in Helicobacter pylori colonization? Glycobiology (2012) 22(8):1077-85. doi:10.1093/glycob/cws076
33. Reis CA, David L, Seixas M, Burchell J, Sobrinho-Simoes M. Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. Int J Cancer (1998) 79(4):402-10. doi:10.1002/(SICI)1097-0215(19980821)79:4<402::AID-IJC16>3.0.CO;2-6
34. Tian H, Miyoshi E, Kawaguchi N, Shaker M, Ito Y, Taniguchi N, et al. The implication of N-acetylglucosaminyltransferase V expression in gastric cancer. Pathobiology (2008) 75(5):288-94. doi:10.1159/000151709
35. Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med (2000) 6(3):306-12. doi:10.1038/73163
36. Taniguchi N, Korekane H. Branched N-glycans and their implications for cell adhesion, signaling and clinical applications for cancer biomarkers and in therapeutics. BMB Rep (2011) 44(12):772-81. doi:10.5483/BMBRep.2011.44.12.772
37. Balog CI, Stavenhagen K, Fung WL, Koeleman CA, McDonnell LA, Verhoeven A, et al. N-glycosylation of colorectal cancer tissues: a liquid chromatography and mass spectrometry-based investigation. Mol Cell Proteomics (2012) 11(9):571-85. doi:10.1074/mcp. M111.011601
38. Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta (1999) 1473(1):21-34. doi:10.1016/S0304-4165(99)00167-1
39. Fernandes B, Sagman U, Auger M, Demetrio M, Dennis JW. Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res (1991) 51(2):718-23
40. Seelentag WK, Li WP, Schmitz SF, Metzger U, Aeberhard P, Heitz PU, et al. Prognostic value of beta1,6-branched oligosaccharides in human colorectal carcinoma. Cancer Res (1998) 58(23):5559-64
41. Murata K, Miyoshi E, Kameyama M, Ishikawa O, Kabuto T, Sasaki Y, et al. Expression of N-acetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis. Clin Cancer Res (2000) 6(5):1772-7
42. Guo H, Nagy T, Pierce M. Post-translational glycoprotein modifications regulate colon cancer stem cells and colon adenoma progression in Apc(min/+) mice through altered Wnt receptor signaling. J Biol Chem (2014) 289(45):31534-49. doi:10.1074/jbc. M114.602680
43. Ishida H, Togayachi A, Sakai T, Iwai T, Hiruma T, Sato T, et al. A novel beta1,3-N-acetylglucosaminyltransferase (beta3Gn-T8), which synthesizes poly-N-acetyllactosamine, is dramatically upregulated in colon cancer. FEBS Lett (2005) 579(1):71-8. doi:10.1016/j.febslet.2004.11.037
44. Park HM, Hwang MP, Kim YW, Kim KJ, Jin JM, Kim YH, et al. Mass spectrometry-based N-linked glycomic profiling as a means for tracking pancreatic cancer metastasis. Carbohydr Res (2015) 413:5-11. doi:10.1016/j.carres.2015.04.019
45. Zhao J, Qiu W, Simeone DM, Lubman DM. N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. J Proteome Res (2007) 6(3):1126-38. doi:10.1021/pr0604458
46. Gu J, Isaji T, Xu Q, Kariya Y, Gu W, Fukuda T, et al. Potential roles of N-glycosylation in cell adhesion. Glycoconj J (2012) 29(8-9):599-607. doi:10.1007/s10719-012-9386-1
47. Pinho SS, Reis CA, Paredes J, Magalhaes AM, Ferreira AC, Figueiredo J, et al. The role of N-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin. Hum Mol Genet (2009) 18(14):2599-608. doi:10.1093/hmg/ddp194
48. Pinho SS, Osorio H, Nita-Lazar M, Gomes J, Lopes C, Gartner F, et al. Role of E-cadherin N-glycosylation profile in a mammary tumor model. Biochem Biophys Res Commun (2009) 379(4):1091-6. doi:10.1016/j.bbrc.2009.01.024
49. Gu J, Sato Y, Kariya Y, Isaji T, Taniguchi N, Fukuda T. A mutual regulation between cell-cell adhesion and N-glycosylation: implication of the bisecting GlcNAc for biological functions. J Proteome Res (2009) 8(2):431-5. doi:10.1021/pr800674g
50. Yoshimura M, Ihara Y, Matsuzawa Y, Taniguchi N. Aberrant glycosylation of E-cadherin enhances cell-cell binding to suppress metastasis. J Biol Chem (1996) 271(23):13811-5. doi:10.1074/jbc.271.23.13811
51. Kitada T, Miyoshi E, Noda K, Higashiyama S, Ihara H, Matsuura N, et al. The addition of bisecting N-acetylglucosamine residues to E-cadherin down-regulates the tyrosine phosphorylation of beta-catenin. J Biol Chem (2001) 276(1):475-80. doi:10.1074/jbc. M006689200
52. Pinho SS, Figueiredo J, Cabral J, Carvalho S, Dourado J, Magalhaes A, et al. E-cadherin and adherens-junctions stability in gastric carcinoma: functional implications of glycosyltransferases involving N-glycan branching biosynthesis, N-acetylglucosaminyltransferases III and V. Biochim Biophys Acta (2013) 1830(3):2690-700. doi:10.1016/j.bbagen.2012.10.021
53. Pinho SS, Oliveira P, Cabral J, Carvalho S, Huntsman D, Gartner F, et al. Loss and recovery of Mgat3 and GnT-III mediated E-cadherin N-glycosylation is a mechanism involved in epithelial-mesenchymal-epithelial transitions. PLoS One (2012) 7(3):e33191. doi:10.1371/journal.pone.0033191
54. Xu Q, Isaji T, Lu Y, Gu W, Kondo M, Fukuda T, et al. Roles of N-acetylglucosaminyltransferase III in epithelial-to-mesenchymal transition induced by transforming growth factor beta1 (TGF-beta1) in epithelial cell lines. J Biol Chem (2012) 287(20):16563-74. doi:10.1074/jbc. M111.262154
55. Ihara S, Miyoshi E, Ko JH, Murata K, Nakahara S, Honke K, et al. Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding beta 1-6 GlcNAc branching. J Biol Chem (2002) 277(19):16960-7. doi:10.1074/jbc. M200673200
56. Zhao Y, Nakagawa T, Itoh S, Inamori K, Isaji T, Kariya Y, et al. N-acetylglucosaminyltransferase III antagonizes the effect of N-acetylglucosaminyltransferase V on alpha3beta1 integrin-mediated cell migration. J Biol Chem (2006) 281(43):32122-30. doi:10.1074/jbc. M607274200
57. Isaji T, Gu J, Nishiuchi R, Zhao Y, Takahashi M, Miyoshi E, et al. Introduction of bisecting GlcNAc into integrin alpha5beta1 reduces ligand binding and down-regulates cell adhesion and cell migration. J Biol Chem (2004) 279(19):19747-54. doi:10.1074/jbc. M311627200
58. Sato Y, Isaji T, Tajiri M, Yoshida-Yamamoto S, Yoshinaka T, Somehara T, et al. An N-glycosylation site on the beta-propeller domain of the integrin alpha5 subunit plays key roles in both its function and site-specific modification by beta1,4-N-acetylglucosaminyltransferase III. J Biol Chem (2009) 284(18):11873-81. doi:10.1074/jbc. M807660200
59. Dall'Olio F, Chiricolo M. Sialyltransferases in cancer. Glycoconj J (2001) 18(11-12):841-50. doi:10.1023/A:1022288022969
60. Jandus C, Boligan KF, Chijioke O, Liu H, Dahlhaus M, Demoulins T, et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest (2014) 124(4):1810-20. doi:10.1172/JCI65899
61. Laubli H, Pearce OM, Schwarz F, Siddiqui SS, Deng L, Stanczak MA, et al. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc Natl Acad Sci U S A (2014) 111(39):14211-6. doi:10.1073/pnas.1409580111
62. Kim YJ, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J (1997) 14(5):569-76. doi:10.1023/A:1018580324971
63. Dall'Olio F, Malagolini N, Trinchera M, Chiricolo M. Sialosignaling: sialyltransferases as engines of self-fueling loops in cancer progression. Biochim Biophys Acta (2014) 1840(9):2752-64. doi:10.1016/j.bbagen.2014.06.006
64. Lise M, Belluco C, Perera SP, Patel R, Thomas P, Ganguly A. Clinical correlations of alpha2,6-sialyltransferase expression in colorectal cancer patients. Hybridoma (2000) 19(4):281-6. doi:10.1089/027245700429828
65. Gretschel S, Haensch W, Schlag PM, Kemmner W. Clinical relevance of sialyltransferases ST6GAL-I and ST3GAL-III in gastric cancer. Oncology (2003) 65(2):139-45. doi:10.1159/000072339
66. Petretti T, Schulze B, Schlag PM, Kemmner W. Altered mRNA expression of glycosyltransferases in human gastric carcinomas. Biochim Biophys Acta (1999) 1428(2-3):209-18. doi:10.1016/S0304-4165(99)00080-X
67. Gomes C, Osorio H, Pinto MT, Campos D, Oliveira MJ, Reis CA. Expression of ST3GAL4 leads to SLe(x) expression and induces c-Met activation and an invasive phenotype in gastric carcinoma cells. PLoS One (2013) 8(6):e66737. doi:10.1371/journal.pone.0066737
68. Perez-Garay M, Arteta B, Llop E, Cobler L, Pages L, Ortiz R, et al. alpha2,3-sialyltransferase ST3Gal IV promotes migration and metastasis in pancreatic adenocarcinoma cells and tends to be highly expressed in pancreatic adenocarcinoma tissues. Int J Biochem Cell Biol (2013) 45(8):1748-57. doi:10.1016/j.biocel.2013.05.015
69. Perez-Garay M, Arteta B, Pages L, de Llorens R, de Bolos C, Vidal-Vanaclocha F, et al. alpha2,3-sialyltransferase ST3Gal III modulates pancreatic cancer cell motility and adhesion in vitro and enhances its metastatic potential in vivo. PLoS One (2010) 5(9):e12524. doi:10.1371/journal.pone.0012524
70. Bassaganas S, Perez-Garay M, Peracaula R. Cell surface sialic acid modulates extracellular matrix adhesion and migration in pancreatic adenocarcinoma cells. Pancreas (2014) 43(1):109-17. doi:10.1097/MPA.0b013e31829d9090
71. Nakagoe T, Fukushima K, Nanashima A, Sawai T, Tsuji T, Jibiki M, et al. Expression of Lewis(a), sialyl Lewis(a), Lewis(x) and sialyl Lewis(x) antigens as prognostic factors in patients with colorectal cancer. Can J Gastroenterol (2000) 14(9):753-60
72. Satomura Y, Sawabu N, Takemori Y, Ohta H, Watanabe H, Okai T, et al. Expression of various sialylated carbohydrate antigens in malignant and nonmalignant pancreatic tissues. Pancreas (1991) 6(4):448-58. doi:10.1097/00006676-199107000-00012
73. Peracaula R, Tabares G, Lopez-Ferrer A, Brossmer R, de Bolos C, de Llorens R. Role of sialyltransferases involved in the biosynthesis of Lewis antigens in human pancreatic tumour cells. Glycoconj J (2005) 22(3):135-44. doi:10.1007/s10719-005-0734-2
74. Nakagoe T, Sawai T, Tsuji T, Jibiki MA, Nanashima A, Yamaguchi H, et al. Predictive factors for preoperative serum levels of sialy Lewis(x), sialyl Lewis(a) and sialyl Tn antigens in gastric cancer patients. Anticancer Res (2002) 22(1A):451-8
75. Amado M, Carneiro F, Seixas M, Clausen H, Sobrinho-Simoes M. Dimeric sialyl-Le(x) expression in gastric carcinoma correlates with venous invasion and poor outcome. Gastroenterology (1998) 114(3):462-70. doi:10.1016/S0016-5085(98)70529-3
76. Baldus SE, Zirbes TK, Monig SP, Engel S, Monaca E, Rafiqpoor K, et al. Histopathological subtypes and prognosis of gastric cancer are correlated with the expression of mucin-associated sialylated antigens: sialosyl-Lewis(a), sialosyl-Lewis(x) and sialosyl-Tn. Tumour Biol (1998) 19(6):445-53. doi:10.1159/000030036
77. Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, et al. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res (1993) 53(15):3632-7
78. Rosen SD, Bertozzi CR. The selectins and their ligands. Curr Opin Cell Biol (1994) 6(5):663-73. doi:10.1016/0955-0674(94)90092-2
79. Mereiter S, Magalhaes A, Adamczyk B, Jin C, Almeida A, Drici L, et al. Glycomic analysis of gastric carcinoma cells discloses glycans as modulators of RON receptor tyrosine kinase activation in cancer. Biochim Biophys Acta (2015). doi:10.1016/j.bbagen.2015.12.016
80. Wang MH, Lee W, Luo YL, Weis MT, Yao HP. Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol (2007) 213(4):402-11. doi:10.1002/path.2245
81. Thobe MN, Gurusamy D, Pathrose P, Waltz SE. The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells. Oncogene (2010) 29(2):214-26. doi:10.1038/onc.2009.331
82. Logan-Collins J, Thomas RM, Yu P, Jaquish D, Mose E, French R, et al. Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res (2010) 70(3):1130-40. doi:10.1158/0008-5472.CAN-09-0761
83. McClaine RJ, Marshall AM, Wagh PK, Waltz SE. Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines. Neoplasia (2010) 12(8):650-8. doi:10.1593/neo.10476
84. Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, et al. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther (2011) 12(1):9-46. doi:10.4161/cbt.12.1.15747
85. Balmana M, Sarrats A, Llop E, Barrabes S, Saldova R, Ferri MJ, et al. Identification of potential pancreatic cancer serum markers: increased sialyl-Lewis X on ceruloplasmin. Clin Chim Acta (2015) 442:56-62. doi:10.1016/j.cca.2015.01.007
86. Rho JH, Mead JR, Wright WS, Brenner DE, Stave JW, Gildersleeve JC, et al. Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arrays. J Proteomics (2014) 96:291-9. doi:10.1016/j.jprot.2013.10.030
87. Park JJ, Lee M. Increasing the alpha 2, 6 sialylation of glycoproteins may contribute to metastatic spread and therapeutic resistance in colorectal cancer. Gut Liver (2013) 7(6):629-41. doi:10.5009/gnl.2013.7.6.629
88. Miyoshi E, Moriwaki K, Terao N, Tan CC, Terao M, Nakagawa T, et al. Fucosylation is a promising target for cancer diagnosis and therapy. Biomolecules (2012) 2(1):34-45. doi:10.3390/biom2010034
89. Miyoshi E, Moriwaki K, Nakagawa T. Biological function of fucosylation in cancer biology. J Biochem (2008) 143(6):725-9. doi:10.1093/jb/mvn011
90. Breborowicz J, Mackiewicz A, Breborowicz D. Microheterogeneity of alpha-fetoprotein in patient serum as demonstrated by lectin affino-electrophoresis. Scand J Immunol (1981) 14(1):15-20. doi:10.1111/j.1365-3083.1981.tb00179.x
91. Wong RJ, Ahmed A, Gish RG. Elevated alpha-fetoprotein: differential diagnosis-hepatocellular carcinoma and other disorders. Clin Liver Dis (2015) 19(2):309-23. doi:10.1016/j.cld.2015.01.005
92. Balmana M, Gimenez E, Puerta A, Llop E, Figueras J, Fort E, et al. Increased alpha1-3 fucosylation of alpha-1-acid glycoprotein (AGP) in pancreatic cancer. J Proteomics (2015) 132:144-54. doi:10.1016/j.jprot.2015.11.006
93. Trinchera M, Malagolini N, Chiricolo M, Santini D, Minni F, Caretti A, et al. The biosynthesis of the selectin-ligand sialyl Lewis x in colorectal cancer tissues is regulated by fucosyltransferase VI and can be inhibited by an RNA interference-based approach. Int J Biochem Cell Biol (2011) 43(1):130-9. doi:10.1016/j.biocel.2010.10.004
94. Qiu Y, Patwa TH, Xu L, Shedden K, Misek DE, Tuck M, et al. Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J Proteome Res (2008) 7(4):1693-703. doi:10.1021/pr700706s
95. Muinelo-Romay L, Gil-Martin E, Fernandez-Briera A. alpha(1,2)Fucosylation in human colorectal carcinoma. Oncol Lett (2010) 1(2):361-6. doi:10.3892/ol_00000064
96. Lopez-Ferrer A, de Bolos C, Barranco C, Garrido M, Isern J, Carlstedt I, et al. Role of fucosyltransferases in the association between apomucin and Lewis antigen expression in normal and malignant gastric epithelium. Gut (2000) 47(3):349-56. doi:10.1136/gut.47.3.349
97. Duell EJ, Bonet C, Munoz X, Lujan-Barroso L, Weiderpass E, Boutron-Ruault MC, et al. Variation at ABO histo-blood group and FUT loci and diffuse and intestinal gastric cancer risk in a European population. Int J Cancer (2015) 136(4):880-93. doi:10.1002/ijc.29034
98. Magalhaes A, Marcos-Pinto R, Nairn AV, Dela Rosa M, Ferreira RM, Junqueira-Neto S, et al. Helicobacter pylori chronic infection and mucosal inflammation switches the human gastric glycosylation pathways. Biochim Biophys Acta (2015) 1852(9):1928-39. doi:10.1016/j.bbadis.2015.07.001
99. Muinelo-Romay L, Vazquez-Martin C, Villar-Portela S, Cuevas E, Gil-Martin E, Fernandez-Briera A. Expression and enzyme activity of alpha(1,6)fucosyltransferase in human colorectal cancer. Int J Cancer (2008) 123(3):641-6. doi:10.1002/ijc.23521
100. Osumi D, Takahashi M, Miyoshi E, Yokoe S, Lee SH, Noda K, et al. Core fucosylation of E-cadherin enhances cell-cell adhesion in human colon carcinoma WiDr cells. Cancer Sci (2009) 100(5):888-95. doi:10.1111/j.1349-7006.2009.01125.x
101. Zhao YP, Xu XY, Fang M, Wang H, You Q, Yi CH, et al. Decreased core-fucosylation contributes to malignancy in gastric cancer. PLoS One (2014) 9(4):e94536. doi:10.1371/journal.pone.0094536
102. Ma Z, Vosseller K. Cancer metabolism and elevated O-GlcNAc in oncogenic signaling. J Biol Chem (2014) 289(50):34457-65. doi:10.1074/jbc. R114.577718
103. Fardini Y, Dehennaut V, Lefebvre T, Issad T. O-GlcNAcylation: a new cancer hallmark? Front Endocrinol (2013) 4:99. doi:10.3389/fendo.2013.00099
104. Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem (2011) 80:825-58. doi:10.1146/annurev-biochem-060608-102511
105. Konrad RJ, Kudlow JE. The role of O-linked protein glycosylation in beta-cell dysfunction. Int J Mol Med (2002) 10(5):535-9. doi:10.3892/ijmm.10.5.535
106. Ma Z, Vocadlo DJ, Vosseller K. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-kappaB activity in pancreatic cancer cells. J Biol Chem (2013) 288(21):15121-30. doi:10.1074/jbc. M113.470047
107. Yang YR, Kim DH, Seo YK, Park D, Jang HJ, Choi SY, et al. Elevated O-GlcNAcylation promotes colonic inflammation and tumorigenesis by modulating NF-kappaB signaling. Oncotarget (2015) 6(14):12529-42. doi:10.18632/oncotarget.3725
108. Couchman JR, Gopal S, Lim HC, Norgaard S, Multhaupt HA. Syndecans: from peripheral coreceptors to mainstream regulators of cell behaviour. Int J Exp Pathol (2015) 96(1):1-10. doi:10.1111/iep.12112
109. Magalhaes A, Marcos NT, Carvalho AS, David L, Figueiredo C, Bastos J, et al. Helicobacter pylori cag pathogenicity island-positive strains induce syndecan-4 expression in gastric epithelial cells. FEMS Immunol Med Microbiol (2009) 56(3):223-32. doi:10.1111/j.1574-695X.2009.00569.x
110. Marcos NT, Magalhaes A, Ferreira B, Oliveira MJ, Carvalho AS, Mendes N, et al. Helicobacter pylori induces beta3GnT5 in human gastric cell lines, modulating expression of the SabA ligand sialyl-Lewis x. J Clin Invest (2008) 118(6):2325-36. doi:10.1172/JCI34324
111. Wiksten JP, Lundin J, Nordling S, Lundin M, Kokkola A, von Boguslawski K, et al. Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer (2001) 95(1):1-6. doi:10.1002/1097-0215(20010120)95:1<1::AID-IJC1000>3.0.CO;2-5
112. Kim SY, Choi EJ, Yun JA, Jung ES, Oh ST, Kim JG, et al. Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma: a clinicopathological study of 230 cases. Int J Med Sci (2015) 12(2):92-9. doi:10.7150/ijms.10497
113. Conejo JR, KleeffJ, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, et al. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer (2000) 88(1):12-20. doi:10.1002/1097-0215(20001001)88:1<12::AID-IJC3>3.0.CO;2-T
114. Filmus J, Capurro M, Rast J. Glypicans. Genome Biol (2008) 9(5):224. doi:10.1186/gb-2008-9-5-224
115. KleeffJ, Ishiwata T, Kumbasar A, Friess H, Buchler MW, Lander AD, et al. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest (1998) 102(9):1662-73. doi:10.1172/JCI4105
116. Whipple CA, Young AL, Korc M. A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis. Oncogene (2012) 31(20):2535-44. doi:10.1038/onc.2011.430
117. Aikawa T, Whipple CA, Lopez ME, Gunn J, Young A, Lander AD, et al. Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J Clin Invest (2008) 118(1):89-99. doi:10.1172/JCI32412
118. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature (2015) 523(7559):177-82. doi:10.1038/nature14581
119. da Cunha CB, Oliveira C, Wen X, Gomes B, Sousa S, Suriano G, et al. De novo expression of CD44 variants in sporadic and hereditary gastric cancer. Lab Invest (2010) 90(11):1604-14. doi:10.1038/labinvest.2010.155
120. Campos D, Freitas D, Gomes J, Magalhaes A, Steentoft C, Gomes C, et al. Probing the O-glycoproteome of gastric cancer cell lines for biomarker discovery. Mol Cell Proteomics (2015) 14(6):1616-29. doi:10.1074/mcp. M114.046862
121. Haakenson JK, Khokhlatchev AV, Choi YJ, Linton SS, Zhang P, Zaki PM, et al. Lysosomal degradation of CD44 mediates ceramide nanoliposome-induced anoikis and diminished extravasation in metastatic carcinoma cells. J Biol Chem (2015) 290(13):8632-43. doi:10.1074/jbc. M114.609677
122. Miyagi T, Wada T, Yamaguchi K. Roles of plasma membrane-associated sialidase NEU3 in human cancers. Biochim Biophys Acta (2008) 1780(3):532-7. doi:10.1016/j.bbagen.2007.09.016
123. Kakugawa Y, Wada T, Yamaguchi K, Yamanami H, Ouchi K, Sato I, et al. Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. Proc Natl Acad Sci U S A (2002) 99(16):10718-23. doi:10.1073/pnas.152597199
124. Takahashi K, Hosono M, Sato I, Hata K, Wada T, Yamaguchi K, et al. Sialidase NEU3 contributes neoplastic potential on colon cancer cells as a key modulator of gangliosides by regulating Wnt signaling. Int J Cancer (2015) 137(7):1560-73. doi:10.1002/ijc.29527
125. Holst S, Stavenhagen K, Balog CI, Koeleman CA, McDonnell LM, Mayboroda OA, et al. Investigations on aberrant glycosylation of glycosphingolipids in colorectal cancer tissues using liquid chromatography and matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF-MS). Mol Cell Proteomics (2013) 12(11):3081-93. doi:10.1074/mcp. M113.030387
126. Ebeling FG, Stieber P, Untch M, Nagel D, Konecny GE, Schmitt UM, et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer (2002) 86(8):1217-22. doi:10.1038/sj.bjc.6600248
127. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 25(33):5287-312. doi:10.1200/JCO.2007.14.2364
128. Kumpulainen EJ, Keskikuru RJ, Johansson RT. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat (2002) 76(2):95-102. doi:10.1023/A:1020514925143
129. Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol (2008) 13(5):447-51. doi:10.1007/s10147-008-0773-3
130. Lauro S, Trasatti L, Bordin F, Lanzetta G, Bria E, Gelibter A, et al. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Res (1999) 19(4C):3511-5
131. Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ. Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev (2001) 10(5):489-93
132. Gostout BS, Brewer MA. Guidelines for referral of the patient with an adnexal mass. Clin Obstet Gynecol (2006) 49(3):448-58. doi:10.1097/00003081-200609000-00005
133. Gilgunn S, Conroy PJ, Saldova R, Rudd PM, O'Kennedy RJ. Aberrant PSA glycosylation-a sweet predictor of prostate cancer. Nat Rev Urol (2013) 10(2):99-107. doi:10.1038/nrurol.2012.258
134. Saldova R, Fan Y, Fitzpatrick JM, Watson RW, Rudd PM. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology (2011) 21(2):195-205. doi:10.1093/glycob/cwq147
135. SafiF, Schlosser W, Kolb G, Beger HG. Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest Surg (1997) 1(2):106-12. doi:10.1016/S1091-255X(97)80097-2
136. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol (2006) 24(33):5313-27. doi:10.1200/JCO.2006.08.2644
137. Duraker N, Celik AN. The prognostic significance of preoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol (2001) 76(4):266-71. doi:10.1002/jso.1044
138. Shah UA, Saif MW. Tumor markers in pancreatic cancer: 2013. JOP (2013) 14(4):318-21. doi:10.6092/1590-8577/1653
139. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest (2005) 23(4):338-51. doi:10.1081/CNV-58878
140. Steele SR, Chang GJ, Hendren S, Weiser M, Irani J, Buie WD, et al. Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. Dis Colon Rectum (2015) 58(8):713-25. doi:10.1097/DCR.0000000000000410
141. Julien S, Adriaenssens E, Ottenberg K, Furlan A, Courtand G, Vercoutter-Edouart AS, et al. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology (2006) 16(1):54-64. doi:10.1093/glycob/cwj033
142. Julien S, Lagadec C, Krzewinski-Recchi MA, Courtand G, Le Bourhis X, Delannoy P. Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration. Breast Cancer Res Treat (2005) 90(1):77-84. doi:10.1007/s10549-004-3137-3
143. Ma H, Zhou H, Li P, Song X, Miao X, Li Y, et al. Effect of ST3GAL 4 and FUT 7 on sialyl Lewis X synthesis and multidrug resistance in human acute myeloid leukemia. Biochim Biophys Acta (2014) 1842(9):1681-92. doi:10.1016/j.bbadis.2014.06.014
144. Yang XS, Liu S, Liu YJ, Liu JW, Liu TJ, Wang XQ, et al. Overexpression of fucosyltransferase IV promotes A431 cell proliferation through activating MAPK and PI3K/Akt signaling pathways. J Cell Physiol (2010) 225(2):612-9. doi:10.1002/jcp.22250
145. Tsuda T, Ikeda Y, Taniguchi N. The Asn-420-linked sugar chain in human epidermal growth factor receptor suppresses ligand-independent spontaneous oligomerization. Possible role of a specific sugar chain in controllable receptor activation. J Biol Chem (2000) 275(29):21988-94. doi:10.1074/jbc. M003400200
146. van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci (2008) 65(23):3756-88. doi:10.1007/s00018-008-8281-1
147. Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, et al. Epithelial E-and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta (2012) 1826(2):297-311. doi:10.1016/j.bbcan.2012.05.002
148. Oliveira C, Seruca R, Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol (2006) 14(1):21-33. doi:10.1177/106689690601400105
149. Carvalho S, Catarino TA, Dias AM, Kato M, Almeida A, Hessling B, et al. Preventing E-cadherin aberrant N-glycosylation at Asn-554 improves its critical function in gastric cancer. Oncogene (2015). doi:10.1038/onc.2015.225
150. Pinho SS, Seruca R, Gartner F, Yamaguchi Y, Gu J, Taniguchi N, et al. Modulation of E-cadherin function and dysfunction by N-glycosylation. Cell Mol Life Sci (2011) 68(6):1011-20. doi:10.1007/s00018-010-0595-0
151. Steentoft C, Bennett EP, Schjoldager KT, Vakhrushev SY, Wandall HH, Clausen H. Precision genome editing: a small revolution for glycobiology. Glycobiology (2014) 24(8):663-80. doi:10.1093/glycob/cwu046
152. Steentoft C, Vakhrushev SY, Joshi HJ, Kong Y, Vester-Christensen MB, Schjoldager KT, et al. Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. EMBO J (2013) 32(10):1478-88. doi:10.1038/emboj.2013.79
153. Schjoldager KT, Vakhrushev SY, Kong Y, Steentoft C, Nudelman AS, Pedersen NB, et al. Probing isoform-specific functions of polypeptide GalNAc-transferases using zinc finger nuclease glycoengineered SimpleCells. Proc Natl Acad Sci U S A (2012) 109(25):9893-8. doi:10.1073/pnas.1203563109
154. Vakhrushev SY, Steentoft C, Vester-Christensen MB, Bennett EP, Clausen H, Levery SB. Enhanced mass spectrometric mapping of the human GalNAc-type O-glycoproteome with SimpleCells. Mol Cell Proteomics (2013) 12(4):932-44. doi:10.1074/mcp. O112.021972
155. Schjoldager KT, Clausen H. Site-specific protein O-glycosylation modulates proprotein processing-deciphering specific functions of the large polypeptide GalNAc-transferase gene family. Biochim Biophys Acta (2012) 1820(12):2079-94. doi:10.1016/j.bbagen.2012.09.014
156. Vester-Christensen MB, Halim A, Joshi HJ, Steentoft C, Bennett EP, Levery SB, et al. Mining the O-mannose glycoproteome reveals cadherins as major O-mannosylated glycoproteins. Proc Natl Acad Sci U S A (2013) 110(52):21018-23. doi:10.1073/pnas.1313446110
157. Mechref Y. Analysis of glycans derived from glycoconjugates by capillary electrophoresis-mass spectrometry. Electrophoresis (2011) 32(24):3467-81. doi:10.1002/elps.201100342
158. Sethi MK, Kim H, Park CK, Baker MS, Paik YK, Packer NH, et al. In-depth N-glycome profiling of paired colorectal cancer and non-tumorigenic tissues reveals cancer-, stage-and EGFR-specific protein N-glycosylation. Glycobiology (2015) 25(10):1064-78. doi:10.1093/glycob/cwv042
159. Bones J, Byrne JC, O'Donoghue N, McManus C, Scaife C, Boissin H, et al. Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. J Proteome Res (2011) 10(3):1246-65. doi:10.1021/pr101036b
160. Bones J, Mittermayr S, O'Donoghue N, Guttman A, Rudd PM. Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation. Anal Chem (2010) 82(24):10208-15. doi:10.1021/ac102860w
161. Ozcan S, Barkauskas DA, Renee Ruhaak L, Torres J, Cooke CL, An HJ, et al. Serum glycan signatures of gastric cancer. Cancer Prev Res (Phila) (2014) 7(2):226-35. doi:10.1158/1940-6207.CAPR-13-0235
162. Nouso K, Amano M, Ito YM, Miyahara K, Morimoto Y, Kato H, et al. Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer. J Gastroenterol (2013) 48(10):1171-9. doi:10.1007/s00535-012-0732-7
163. Mann BF, Goetz JA, House MG, Schmidt CM, Novotny MV. Glycomic and proteomic profiling of pancreatic cyst fluids identifies hyperfucosylated lactosamines on the N-linked glycans of overexpressed glycoproteins. Mol Cell Proteomics (2012) 11(7):M111015792. doi:10.1074/mcp. M111.015792
164. Kaji H, Saito H, Yamauchi Y, Shinkawa T, Taoka M, Hirabayashi J, et al. Lectin affinity capture, isotope-coded tagging and mass spectrometry to identify N-linked glycoproteins. Nat Biotechnol (2003) 21(6):667-72. doi:10.1038/nbt829
165. Yang Z, Hancock WS. Approach to the comprehensive analysis of glycoproteins isolated from human serum using a multi-lectin affinity column. J Chromatogr A (2004) 1053(1-2):79-88. doi:10.1016/S0021-9673(04)01433-5
166. Durham M, Regnier FE. Targeted glycoproteomics: serial lectin affinity chromatography in the selection of O-glycosylation sites on proteins from the human blood proteome. J Chromatogr A (2006) 1132(1-2):165-73. doi:10.1016/j.chroma.2006.07.070
167. Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol (2003) 21(6):660-6. doi:10.1038/nbt827
168. Liu T, Qian WJ, Gritsenko MA, Camp DG II, Monroe ME, Moore RJ, et al. Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J Proteome Res (2005) 4(6):2070-80. doi:10.1021/pr0502065
169. Rawn JD, Lienhard GE. The binding of boronic acids to chymotrypsin. Biochemistry (1974) 13(15):3124-30. doi:10.1021/bi00712a019
170. Alvarez-Manilla G, Atwood J III, Guo Y, Warren NL, Orlando R, Pierce M. Tools for glycoproteomic analysis: size exclusion chromatography facilitates identification of tryptic glycopeptides with N-linked glycosylation sites. J Proteome Res (2006) 5(3):701-8. doi:10.1021/pr050275j
171. Hagglund P, Bunkenborg J, Elortza F, Jensen ON, RoepstorffP. A new strategy for identification of N-glycosylated proteins and unambiguous assignment of their glycosylation sites using HILIC enrichment and partial deglycosylation. J Proteome Res (2004) 3(3):556-66. doi:10.1021/pr034112b
172. Larsen MR, Hojrup P, RoepstorffP. Characterization of gel-separated glycoproteins using two-step proteolytic digestion combined with sequential microcolumns and mass spectrometry. Mol Cell Proteomics (2005) 4(2):107-19. doi:10.1074/mcp. M400068-MCP200
173. Zhao J, Simeone DM, Heidt D, Anderson MA, Lubman DM. Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum. J Proteome Res (2006) 5(7):1792-802. doi:10.1021/pr060034r
174. Melo-Braga MN, Ibanez-Vea M, Larsen MR, Kulej K. Comprehensive protocol to simultaneously study protein phosphorylation, acetylation, and N-linked sialylated glycosylation. Methods Mol Biol (2015) 1295:275-92. doi:10.1007/978-1-4939-2550-6_21
175. Hang HC, Yu C, Kato DL, Bertozzi CR. A metabolic labeling approach toward proteomic analysis of mucin-type O-linked glycosylation. Proc Natl Acad Sci U S A (2003) 100(25):14846-51. doi:10.1073/pnas.2335201100
176. Laughlin ST, Bertozzi CR. Metabolic labeling of glycans with azido sugars and subsequent glycan-profiling and visualization via Staudinger ligation. Nat Protoc (2007) 2(11):2930-44. doi:10.1038/nprot.2007.422
177. Liang Y, Hua Q, Pan P, Yang J, Zhang Q. Development of a novel method to evaluate sialylation of glycoproteins and analysis of gp96 sialylation in Hela, SW1990 and A549 cell lines. Biol Res (2015) 48:52. doi:10.1186/s40659-015-0041-8
178. Wuhrer M, Catalina MI, Deelder AM, Hokke CH. Glycoproteomics based on tandem mass spectrometry of glycopeptides. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 849(1-2):115-28. doi:10.1016/j.jchromb.2006.09.041
179. An HJ, Froehlich JW, Lebrilla CB. Determination of glycosylation sites and site-specific heterogeneity in glycoproteins. Curr Opin Chem Biol (2009) 13(4):421-6. doi:10.1016/j.cbpa.2009.07.022
180. Hinneburg H, Stavenhagen K, Schweiger-Hufnagel U, Pengelley S, Jabs W, Seeberger PH, et al. The art of destruction: optimizing collision energies in quadrupole-time of flight (Q-TOF) instruments for glycopeptide-based glycoproteomics. J Am Soc Mass Spectrom (2016) 27(3):507-19. doi:10.1007/s13361-015-1308-6
181. Gomes C, Almeida A, Ferreira JA, Silva L, Santos-Sousa H, Pinto-de-Sousa J, et al. Glycoproteomic analysis of serum from patients with gastric precancerous lesions. J Proteome Res (2013) 12(3):1454-66. doi:10.1021/pr301112x
182. Li K, Sun Z, Zheng J, Lu Y, Bian Y, Ye M, et al. In-depth research of multidrug resistance related cell surface glycoproteome in gastric cancer. J Proteomics (2013) 82:130-40. doi:10.1016/j.jprot.2013.02.021
183. Chang TW. Binding of cells to matrixes of distinct antibodies coated on solid surface. J Immunol Methods (1983) 65(1-2):217-23. doi:10.1016/0022-1759(83)90318-6
184. Rakus JF, Mahal LK. New technologies for glycomic analysis: toward a systematic understanding of the glycome. Annu Rev Anal Chem (Palo Alto Calif) (2011) 4:367-92. doi:10.1146/annurev-anchem-061010-113951
185. Patwa T, Li C, Simeone DM, Lubman DM. Glycoprotein analysis using protein microarrays and mass spectrometry. Mass Spectrom Rev (2010) 29(5):830-44. doi:10.1002/mas.20269
186. Gao C, Liu Y, Zhang H, Zhang Y, Fukuda MN, Palma AS, et al. Carbohydrate sequence of the prostate cancer-associated antigen F77 assigned by a mucin O-glycome designer array. J Biol Chem (2014) 289(23):16462-77. doi:10.1074/jbc. M114.558932
187. Blixt O, Head S, Mondala T, Scanlan C, Huflejt ME, Alvarez R, et al. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci U S A (2004) 101(49):17033-8. doi:10.1073/pnas.0407902101
188. Schneider C, Smith DF, Cummings RD, Boligan KF, Hamilton RG, Bochner BS, et al. The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites. Sci Transl Med (2015) 7(269):269ra1. doi:10.1126/scitranslmed.3010524
189. Horlacher T, Seeberger PH. Carbohydrate arrays as tools for research and diagnostics. Chem Soc Rev (2008) 37(7):1414-22. doi:10.1039/b708016f
190. Seeberger PH. Automated carbohydrate synthesis as platform to address fundamental aspects of glycobiology-current status and future challenges. Carbohydr Res (2008) 343(12):1889-96. doi:10.1016/j.carres.2008.05.023
191. Wang D, Liu S, Trummer BJ, Deng C, Wang A. Carbohydrate microarrays for the recognition of cross-reactive molecular markers of microbes and host cells. Nat Biotechnol (2002) 20(3):275-81. doi:10.1038/nbt0302-275
192. Liu Y, Palma AS, Feizi T. Carbohydrate microarrays: key developments in glycobiology. Biol Chem (2009) 390(7):647-56. doi:10.1515/BC.2009.071
193. Stevens J, Blixt O, Paulson JC, Wilson IA. Glycan microarray technologies: tools to survey host specificity of influenza viruses. Nat Rev Microbiol (2006) 4(11):857-64. doi:10.1038/nrmicro1530
194. Xuan P, Zhang Y, Tzeng TR, Wan XF, Luo F. A quantitative structure-activity relationship (QSAR) study on glycan array data to determine the specificities of glycan-binding proteins. Glycobiology (2012) 22(4):552-60. doi:10.1093/glycob/cwr163
195. Kletter D, Singh S, Bern M, Haab BB. Global comparisons of lectin-glycan interactions using a database of analyzed glycan array data. Mol Cell Proteomics (2013) 12(4):1026-35. doi:10.1074/mcp. M112.026641
196. Cholleti SR, Agravat S, Morris T, Saltz JH, Song X, Cummings RD, et al. Automated motif discovery from glycan array data. OMICS (2012) 16(10):497-512. doi:10.1089/omi.2012.0013
197. Fair RJ, Hahm HS, Seeberger PH. Combination of automated solid-phase and enzymatic oligosaccharide synthesis provides access to alpha(2,3)-sialylated glycans. Chem Commun (Camb) (2015) 51(28):6183-5. doi:10.1039/c5cc01368b
198. Lai CH, Hahm HS, Liang CF, Seeberger PH. Automated solid-phase synthesis of oligosaccharides containing sialic acids. Beilstein J Org Chem (2015) 11:617-21. doi:10.3762/bjoc.11.69
199. Liang CF, Hahm HS, Seeberger PH. Automated synthesis of chondroitin sulfate oligosaccharides. Methods Mol Biol (2015) 1229:3-10. doi:10.1007/978-1-4939-1714-3_1
200. Zacco E, Anish C, Martin CE, V Berlepsch H, Brandenburg E, Seeberger PH, et al. A self-assembling peptide scaffold for the multivalent presentation of antigens. Biomacromolecules (2015) 16(7):2188-97. doi:10.1021/acs.biomac.5b00572
201. Zhao J, Patwa TH, Qiu W, Shedden K, Hinderer R, Misek DE, et al. Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. J Proteome Res (2007) 6(5):1864-74. doi:10.1021/pr070062p
202. Pedersen JW, Blixt O, Bennett EP, Tarp MA, Dar I, Mandel U, et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer (2011) 128(8):1860-71. doi:10.1002/ijc.25778
203. Burford B, Gentry-Maharaj A, Graham R, Allen D, Pedersen JW, Nudelman AS, et al. Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. Br J Cancer (2013) 108(10):2045-55. doi:10.1038/bjc.2013.214
204. Hirabayashi J, Yamada M, Kuno A, Tateno H. Lectin microarrays: concept, principle and applications. Chem Soc Rev (2013) 42(10):4443-58. doi:10.1039/c3cs35419a
205. Tang H, Hsueh P, Kletter D, Bern M, Haab B. The detection and discovery of glycan motifs in biological samples using lectins and antibodies: new methods and opportunities. Adv Cancer Res (2015) 126:167-202. doi:10.1016/bs.acr.2014.11.003
206. Yue T, Haab BB. Microarrays in glycoproteomics research. Clin Lab Med (2009) 29(1):15-29. doi:10.1016/j.cll.2009.01.001
207. Huang WL, Li YG, Lv YC, Guan XH, Ji HF, Chi BR. Use of lectin microarray to differentiate gastric cancer from gastric ulcer. World J Gastroenterol (2014) 20(18):5474-82. doi:10.3748/wjg.v20.i18.5474
208. Sunderic M, Sediva A, Robajac D, Miljus G, Gemeiner P, Nedic O, et al. Lectin-based protein microarray analysis of differences in serum alpha-2-macroglobulin glycosylation between patients with colorectal cancer and persons without cancer. Biotechnol Appl Biochem (2015). doi:10.1002/bab.1407
209. Cao Z, Maupin K, Curnutte B, Fallon B, Feasley CL, Brouhard E, et al. Specific glycoforms of MUC5AC and endorepellin accurately distinguish mucinous from nonmucinous pancreatic cysts. Mol Cell Proteomics (2013) 12(10):2724-34. doi:10.1074/mcp. M113.030700
210. Chen S, LaRoche T, Hamelinck D, Bergsma D, Brenner D, Simeone D, et al. Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat Methods (2007) 4(5):437-44. doi:10.1038/nmeth1035
211. Kumada Y, Ohigashi Y, Emori Y, Imamura K, Omura Y, Kishimoto M. Improved lectin ELISA for glycosylation analysis of biomarkers using PS-tag-fused single-chain Fv. J Immunol Methods (2012) 385(1-2):15-22. doi:10.1016/j.jim.2012.07.021
212. Gustafsdottir SM, Schallmeiner E, Fredriksson S, Gullberg M, Soderberg O, Jarvius M, et al. Proximity ligation assays for sensitive and specific protein analyses. Anal Biochem (2005) 345(1):2-9. doi:10.1016/j.ab.2005.01.018
213. Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods (2006) 3(12):995-1000. doi:10.1038/nmeth947
214. Conze T, Carvalho AS, Landegren U, Almeida R, Reis CA, David L, et al. MUC2 mucin is a major carrier of the cancer-associated sialyl-Tn antigen in intestinal metaplasia and gastric carcinomas. Glycobiology (2010) 20(2):199-206. doi:10.1093/glycob/cwp161
215. Pinto R, Carvalho AS, Conze T, Magalhaes A, Picco G, Burchell JM, et al. Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation. J Cell Mol Med (2012) 16(7):1474-84. doi:10.1111/j.1582-4934.2011.01436.x
216. Koos B, Kamali-Moghaddam M, David L, Sobrinho-Simoes M, Dimberg A, Nilsson M, et al. Next-generation pathology-surveillance of tumor microecology. J Mol Biol (2015) 427(11):2013-22. doi:10.1016/j.jmb.2015.02.017
217. Caprioli RM, Farmer TB, Gile J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem (1997) 69(23):4751-60. doi:10.1021/ac970888i
218. Powers TW, Jones EE, Betesh LR, Romano PR, Gao P, Copland JA, et al. Matrix assisted laser desorption ionization imaging mass spectrometry workflow for spatial profiling analysis of N-linked glycan expression in tissues. Anal Chem (2013) 85(20):9799-806. doi:10.1021/ac402108x
219. Powers TW, Neely BA, Shao Y, Tang H, Troyer DA, Mehta AS, et al. MALDI imaging mass spectrometry profiling of N-glycans in formalin-fixed paraffin embedded clinical tissue blocks and tissue microarrays. PLoS One (2014) 9(9):e106255. doi:10.1371/journal.pone.0106255
220. Powers TW, Holst S, Wuhrer M, Mehta AS, Drake RR. Two-dimensional N-glycan distribution mapping of hepatocellular carcinoma tissues by MALDI-imaging mass spectrometry. Biomolecules (2015) 5(4):2554-72. doi:10.3390/biom5042554